Cover Image
市場調查報告書

抗生素:技術和全球市場

Antibiotics: Technologies and Global Markets

出版商 BCC Research 商品編碼 103308
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
Back to Top
抗生素:技術和全球市場 Antibiotics: Technologies and Global Markets
出版日期: 2016年03月21日 內容資訊: 英文 157 Pages
簡介

全球全身性的抗生素市值從2015年的406億美元,預計今後以2.0%的年複合成長率成長,到2020年達到447億美元

本報告提供全球全身性的抗生素市場相關調查,市場概要,世界市場趨勢分析(實際成果資料、年複合成長率預測),市場影響因素的詳細分析,重要的趨勢、產品相關的討論,及主要企業整體性簡介等。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 細菌
  • 克陽性菌
  • 革蘭氏陰性菌
  • 細菌感染疾病
  • 呼吸系統感染疾病
  • 肺炎
  • 結核
  • 抗生素定義
  • 抗生素的歷史和現狀
  • 抗生素抗性菌
  • 抗生素維持時代的來到
  • 促進要素、阻礙要素、機會
  • 主要企業的市場佔有率
  • 抗生素的價值鏈
  • 法規的問題
  • 影響市場的主要趨勢

第4章 抗生素的研究開發

  • 在抗生素的研究中欠缺創新的理由
  • 推動抗生素調查的策略
  • 稀少藥物的地位

第5章 抗生素市場:各類型

  • 市場規模估計
  • 市場佔有率估計
  • 全球抗生素市場:各級
  • β內醯胺類抗生素
  • 奎諾酮類抗生素(Quinolones)、Fluoroquinolones
  • 四環黴素
  • 大環內酯類
  • 其他抗生素

第6章 動物用抗生素市場

  • 簡介
  • 動物用應用
  • 其他應用

第7章 企業簡介

第8章 抗生素相關臨床實驗

  • 階段II臨床實驗的抗生素
  • 階段I臨床實驗的抗生素

第9章 細菌種類概要

  • 病原體,診斷,臨床表現及治療

第10章 縮寫清單

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM025D

REPORT HIGHLIGHTS

The global systemic antibiotics market should reach nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.

This report provides:

  • An overview of the global markets and related technologies for antibiotics.
  • Analyses of global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Breakdowns of the market by human application and veterinary application
  • A look at major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets
  • Profiles of key players in the market and analysis of their core competencies and market shares
  • Detailed coverage of
    • Beta-lactams.
      • Penicillin.
      • Cephalosporins.
      • Carbapenems.
    • Fluoroquinolones.
      • Second generation.
      • Third generation.
      • Others.
    • Macrolides.
    • Tetracycline.
    • Other antibiotic classes.

SCOPE OF REPORT

This research report categorizes the systemic antibiotics market into the following segments:

Antibiotics market (human application) by product:

  • Beta-lactams.
    • Penicillin.
    • Cephalosporins.
    • Carbapenems.
  • Fluoroquinolones.
    • Second generation.
    • Third generation.
    • Others.
  • Macrolides.
  • Tetracycline.
  • Other antibiotic classes.
  • Antibiotics market by application:
  • Human applications.
  • Veterinary applications.

Launch of any new antibiotics during the forecast period has not been accounted in the market.

ANALYST'S CREDENTIALS

Neha Maliwal, a graduate in biotechnology and a postgraduate in marketing and biotechnology from the University of Pune (India), is the author of this study and numerous others, including the analyses of related markets such as radiopharmaceuticals, healthcare analytics, radiotherapy devices, healthcare business process outsourcing (BPO), and biotechnology instrumentation.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • RESEARCH METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)

CHAPTER 3 - MARKET OVERVIEW

  • INTRODUCTION
  • BACTERIA
    • TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
  • GRAM-POSITIVE BACTERIA
  • GRAM-NEGATIVE BACTERIA
    • Mycobacterium
      • TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
  • BACTERIAL INFECTIONS
  • RESPIRATORY TRACT INFECTIONS
    • Upper Respiratory Tract Infection
      • TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
      • TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • Lower Respiratory Tract Infection
  • PNEUMONIA
    • TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
    • Community-acquired Pneumonia
    • Hospital-acquired Pneumonia
      • TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
      • TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
  • TUBERCULOSIS
    • URINARY TRACT INFECTIONS (UTI)
      • TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • SKIN AND SKIN STRUCTURE INFECTIONS
      • TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
      • Cellulitis and Erysipelas
      • Folliculitis
      • Impetigo and Ecthyma
      • Abscesses
      • Carbuncles and Furuncles
    • GYNECOLOGICAL INFECTIONS
      • TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
  • DEFINITION OF ANTIBIOTIC
    • CLASSIFICATION OF ANTIBIOTICS
      • FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
  • HISTORY OF ANTIBIOTICS AND CURRENT STATUS
    • PRE-ANTIBIOTIC ERA
    • ANTIBIOTIC ERA
      • TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
      • TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
  • ANTIBIOTIC-RESISTANT BACTERIA
    • MECHANISM OF RESISTANCE
      • TABLE 13: ANTIBIOTICS: MODE OF ACTION
      • Mechanisms of Antimicrobial Resistance
        • TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
      • Methods for the Dissemination of Antimicrobial Resistance Genes
      • Resistance to B-Lactam Antibiotics
      • Tetracycline Resistance
      • Chloramphenicol Resistance
      • Aminoglycoside Resistance
      • Quinolone Resistance
      • Macrolide, Lincosamide, and Streptogramin (MLS) Resistance
      • Glycopeptide Resistance
      • Sulfonamides and Trimethoprim Resistance
      • Multidrug Resistance
        • TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
        • TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
  • EMERGENCE OF POST-ANTIBIOTIC ERA
    • TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
    • FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
    • TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
    • Limitation of Antibiotics
    • Some Antibiotics are Active against Only Certain Kinds of Bacteria
    • Some Bacteria are Virulent and Can Kill Quickly
    • Some Bacteria Grow in Biofilms that cannot be Easily Penetrated by Antibiotics
  • DRIVERS RESTRAINTS AND OPPORTUNITIES
    • DRIVERS
      • Growth of the Global Pharmaceutical Market Driven by Antibiotics
      • Aging Population Propels the Growth of the Antibiotics Market
        • FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
      • Public-Private Partnerships Encourage Antibiotic Development
      • Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth
    • RESTRAINTS
      • Antibiotic Resistance
      • Declining R&D Investment Poses Long-Term Barrier to Market Growth
      • Genericization of Antibiotics Restrains Market Growth
    • OPPORTUNITIES
      • Market Expansion into Emerging Countries
      • Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents
    • BURNING ISSUE
      • New Antibiotic Discovered From Soil
  • MARKET SHARES OF KEY COMPANIES
    • FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
  • VALUE CHAIN OF ANTIBIOTICS
    • CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS
  • REGULATORY ISSUES
    • FDA AND INTERNATIONAL REGULATORY AGENCIES
    • RECENT REGULATORY REFORMS
    • KETEK CASE STUDY
  • KEY TRENDS AFFECTING THE MARKET
    • NEVER EVENTS
      • Impact on the Use of Antibiotics
    • FUNDING FOR NEW ANTIBIOTICS
      • United States
        • Infectious Diseases Society of America
        • NIH Funding
        • Public-Private Partnerships
      • Europe
        • Innovative Medicines Initiative
    • EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION
      • PharmaSea Project
      • Combination of Different Antibiotics
      • Others

CHAPTER 4 - ANTIBIOTIC RESEARCH AND DEVELOPMENT

  • REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • LOW RETURN ON INVESTMENT
    • STRICT REGULATORY ENVIRONMENT
    • SCIENTIFIC CHALLENGES
    • STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
      • FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
    • PUSH STRATEGIES
      • Increasing Access to Research
      • Increasing the Number of Scientific Personnel
      • Direct Funding of Research
      • Translational Research
      • Tax Incentives
      • Product Development Partnerships
    • PULL STRATEGIES
      • Monetary Awards
      • Advance Market Commitments
      • Legal and Regulatory Initiatives
      • Clinical Trials
      • Accelerated Regulatory Review
      • Intellectual Property Rights Strategies
        • Increasing the Term of IP Protection and Data Exclusivity
        • Wildcard Patent Extension
        • Patent Buyouts
      • Pricing and Reimbursement
      • Other Legal/Regulatory Strategies
  • COMBINED PULL AND PUSH INCENTIVES
  • ORPHAN DRUG STATUS
    • TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
    • Delinkage of Antibiotics
      • TABLE 20: LIST OF DELINKAGE MODELS
      • TABLE 21: LIST OF HYBRID MODELS

CHAPTER 5 - ANTIBIOTICS MARKET BY TYPE

  • MARKET SIZE ESTIMATION
  • MARKET SHARE ESTIMATION
  • GLOBAL ANTIBIOTICS MARKET BY CLASS
    • TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7: ANTIBIOTICS BY CLASS
  • BETA-LACTAM ANTIBIOTICS
    • TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • Extended Spectrum Beta-Lactamase
    • Metallo-Beta-Lactamases
      • FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
    • Penicillins
      • TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • Types of Penicillin
      • TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
    • Cephalosporins
    • Side Effects
      • TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • Teflaro Driving the Cephalosporin Market
    • Generations of Cephalosporins
      • TABLE 29: GENERATIONS OF CEPHALOSPORIN
    • First-Generation Cephalosporins
      • TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
    • Second-Generation Cephalosporins
      • TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
    • Third-Generation Cephalosporins
    • Antipseudomonal Cephalosporins
      • TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
    • Fourth-Generation Cephalosporins
      • TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
    • Fifth-Generation Cephalosporins
      • TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
    • Carbapenems
      • TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
      • TABLE 36: TYPES OF CARBAPENEMS
  • QUINOLONES AND FLUOROQUINOLONES
    • TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
    • TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • Generations of Quinolones
      • First-Generation Quinolones
      • Second-Generation Fluoroquinolones
        • TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
      • Third-Generation Fluoroquinolones
        • TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
        • Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones
        • Fourth-Generation Fluoroquinolones
          • TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
          • TABLE 43: TYPES OF QUINOLONES
  • TETRACYCLINE
    • TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: TYPES OF TETRACYCLINE
  • MACROLIDES
    • TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
    • Ketolides
      • Ketek
        • TABLE 47: TYPES OF MACROLIDES/KETOLIDES
  • OTHER ANTIBIOTICS
    • Pseudomonas Aeruginosa
      • TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - VETERINARY ANTIBIOTICS MARKET

  • INTRODUCTION
    • TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
    • TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • VETERINARY APPLICATIONS
    • FEED APPLICATION
      • FDA to Phase out Antibiotics from Food Production
    • THERAPEUTIC APPLICATIONS
      • TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
  • OTHER APPLICATIONS

CHAPTER 7 - COMPANY PROFILES

  • ASTRAZENECA
    • FINANCIALS
      • TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 54: ASTRAZENECA DEVELOPMENTS
  • BAYER HEALTHCARE AG
    • FINANCIALS
      • TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
  • CUBIST PHARMACEUTICALS
    • DEVELOPMENTS
      • TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
  • GLAXOSMITHKLINE
    • FINANCIALS
      • TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 58 GSK DEVELOPMENTS
  • JOHNSON & JOHNSON
    • FINANCIALS
      • TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
  • MERCK & CO.
    • FINANCIALS
      • TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 62: MERCK & CO.DEVELOPMENTS
  • PFIZER
    • FINANCIALS
      • TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • DEVELOPMENTS
      • TABLE 64: PFIZER DEVELOPMENTS
    • RECENT MERGERS AND ACQUISITIONS
      • TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET

CHAPTER 8 - CLINICAL TRIALS ON ANTIBIOTICS

  • FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
  • TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
  • ANTIBIOTICS IN PHASE II CLINICAL TRIALS
    • TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
  • ANTIBIOTICS IN PHASE I CLINICAL TRIALS
    • TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
    • TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015

CHAPTER 9 - OVERVIEW OF BACTERIA TYPES

  • DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS
    • TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
    • TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
    • TABLE 72: LIST OF GRAM-NEGATIVE COCCI
    • TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
    • TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
    • TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
    • TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
    • TABLE 77: LIST OF MISCELLANEOUS BACTERIA

CHAPTER 10 - LIST OF ACRONYMS

  • LIST OF ACRONYMS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA
    • TABLE 2: CLASSIFICATION OF BACTERIA BY SHAPE
    • TABLE 3: PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS
    • TABLE 4: INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 5: COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA
    • TABLE 6: PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA
    • TABLE 7: INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 8: INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 9: INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 10: INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)
    • TABLE 11: U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)
    • TABLE 12: ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES
    • TABLE 13: ANTIBIOTICS: MODE OF ACTION
    • TABLE 14: ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)
    • TABLE 15: TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE
    • TABLE 16: CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA
    • TABLE 17: BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE
    • TABLE 18: ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION
    • TABLE 19: COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS
    • TABLE 20: LIST OF DELINKAGE MODELS
    • TABLE 21: LIST OF HYBRID MODELS
    • TABLE 22: GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 27: TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
    • TABLE 28: GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 29: GENERATIONS OF CEPHALOSPORIN
    • TABLE 30: LIST OF FIRST-GENERATION CEPHALOSPORINS
    • TABLE 31: LIST OF SECOND-GENERATION CEPHALOSPORINS
    • TABLE 32: LIST OF THIRD-GENERATION CEPHALOSPORINS
    • TABLE 33: LIST OF FOURTH-GENERATION CEPHALOSPORINS
    • TABLE 34: LIST OF FIFTH-GENERATION CEPHALOSPORINS
    • TABLE 35: GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: TYPES OF CARBAPENEMS
    • TABLE 37: DEVELOPMENT HISTORY OF FLUOROQUINOLONES
    • TABLE 38: GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 40: GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 43: TYPES OF QUINOLONES
    • TABLE 44: GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: TYPES OF TETRACYCLINE
    • TABLE 46: GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: TYPES OF MACROLIDES/KETOLIDES
    • TABLE 48: GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS
    • TABLE 50: GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: ASTRAZENECA REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 54: ASTRAZENECA DEVELOPMENTS
    • TABLE 55: BAYER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 56: CUBIST PHARMACEUTICAL DEVELOPMENTS
    • TABLE 57: GSK REVENUES AND R & D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 58: GSK DEVELOPMENTS
    • TABLE 59: JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 60: JOHNSON & JOHNSON DEVELOPMENTS
    • TABLE 61: MERCK & CO. REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 62: MERCK & CO.DEVELOPMENTS
    • TABLE 63: PFIZER REVENUES AND R &D EXPENDITURES, 2012-2014 ($ MILLIONS/%)
    • TABLE 64: PFIZER DEVELOPMENTS
    • TABLE 65: LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET
    • TABLE 66: ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015
    • TABLE 67: ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015
    • TABLE 68: ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015
    • TABLE 69: NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015
    • TABLE 70: LIST OF GRAM-POSITIVE BACTERIA
    • TABLE 71: LIST OF GRAM-NEGATIVE BACTERIA
    • TABLE 72: LIST OF GRAM-NEGATIVE COCCI
    • TABLE 73: LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS
    • TABLE 74: LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT
    • TABLE 75: LIST OF GRAM-NEGATIVE SPIROCHETES
    • TABLE 76: LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES
    • TABLE 77: LIST OF MISCELLANEOUS BACTERIA

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ MILLIONS)
    • FIGURE 1: CLASSIFICATION OF ANTIBIOTICS
    • FIGURE 2: CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL
    • FIGURE 3: INCREASE IN AGING POPULATION, 2011 AND 2050
    • FIGURE 4: GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)
    • FIGURE 5: REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH
    • FIGURE 6: STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH
    • FIGURE 7: ANTIBIOTICS BY CLASS
    • FIGURE 8: TYPES OF BETA-LACTAM ANTIBIOTICS
    • FIGURE 9: ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
Back to Top